December 2024—Pillar Biosciences has been granted a unique CPT proprietary laboratory analyses code 0523U from the American Medical Association for its FDA-approved OncoReveal CDx pan-cancer solid tumor in vitro diagnostic NGS kit. OncoReveal CDx uses Pillar’s proprietary SLIMamp (stem-loop inhibition-mediated amplification) technology for detecting single nucleotide variants, insertions, and deletions in 22 genes using DNA isolated from FFPE tumor tissue specimens and is cleared on the Illumina MiSeq Dx. The assay has also been approved as a companion diagnostic to identify patients who may benefit from EGFR TKI therapy in non-small cell lung cancer and Erbitux and Vectibix for KRAS in colorectal cancer.
Pillar Biosciences, 508-655-3027